<DOC>
	<DOCNO>NCT00449137</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil leucovorin , work different way stop growth tumor cell , either kill cell stop dividing . Arsenic trioxide may help fluorouracil leucovorin work well make tumor cell sensitive drug . Giving arsenic trioxide together fluorouracil leucovorin may kill tumor cell . PURPOSE : This phase I trial study side effect best dose arsenic trioxide fluorouracil give together leucovorin treat patient stage IV colorectal cancer relapse respond treatment .</brief_summary>
	<brief_title>Arsenic Trioxide , Fluorouracil , Leucovorin Treating Patients With Stage IV Colorectal Cancer That Has Relapsed Not Responded Treatment</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose best dose combination fluorouracil arsenic trioxide give together leucovorin calcium patient relapse refractory stage IV colorectal cancer . - Determine arsenic trioxide regulate expression thymidylate synthase tumor peripheral blood mononuclear cell patient . OUTLINE : This dose-escalation study fluorouracil arsenic trioxide . Patients receive arsenic trioxide IV 1-4 hour day 1-5 , 8 , 11 , 15 , 18 , 22 fluorouracil IV 24 hour leucovorin calcium IV 24 hour day 8 , 15 , 22 . Treatment repeat every 5 week 8 course absence disease progression unacceptable toxicity . Cohorts 1-6 patient receive escalate dos fluorouracil arsenic trioxide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . Patients undergo peripheral blood mononuclear cell ( PBMC ) collection fine-needle tumor aspiration periodically determine effect arsenic trioxide thymidylate synthase expression tumor PBMCs . After completion study treatment , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal cancer Stage IV disease ( i.e. , T , N , M1 disease ) Relapsed refractory disease Disease progress ≥ 2 different fluorouracilcontaining chemotherapy regimen ( e.g. , irinotecan hydrochloride oxaliplatin without bevacizumab ) Bidimensionally measurable disease Must tumor amenable biopsy willing undergo fineneedle aspiration No CNS metastases PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 2 month Platelet count &gt; 100,000/mm^3 WBC ≥ 3,000/mm^3 Creatinine ≤ 1.5 time upper limit normal Bilirubin ≤ 2 time normal SGOT ≤ 5 time normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 4 month completion study treatment No preexist peripheral neuropathy ≥ grade 2 Ejection fraction ≥ 30 % Baseline QT interval &lt; 500 msec No serious underlie medical illness active infection No underlying medical condition could aggravate treatment No lifethreatening disease unrelated colorectal cancer No malignancy within past 5 year unless currently diseasefree therapy malignancy complete No preexist neurological disorder ( i.e. , seizure disorder ) ≥ grade 3 No cardiac disease , include follow : Recurrent supraventricular arrhythmia Any type sustain ventricular arrhythmia conduction block ( e.g. , grade II III atrioventricular block leave bundle branch block ) Uncontrolled ischemic heart disease History nonsustained ventricular tachycardia Prolonged PR interval ( i.e. , 1st degree heart block ) No know hypersensitivity arsenic trioxide fluorouracil No history allergic reaction attribute compound similar biologic composition arsenic trioxide fluorouracil PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered treatmentrelated toxicity At least 4 week since prior chemotherapy radiotherapy recover More 4 week since prior investigational drug No concurrent investigational commercial anticancer agent therapy Concurrent local radiotherapy allow symptom relief ( e.g. , significant onset pain enrollment , begin study therapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>